Cabaletta Bio, Inc.

NASDAQ:CABA

Biotechnology

Healthcare
$1.06 +1.23%

+$0.04 today

Market cap
$227.58M
Beta
3.23
P/E (TTM)
-1.8
EPS (TTM)
-$1.57
52W Low $1.26High $4.23

Volume 4.13M

Average 3.33M

CABA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Cabaletta Bio, Inc.NASDAQ: CABA

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $0.

Context

  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How CABA compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
CABA Competitors
Cost of Revenue for CABA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$77.25M USD-23.8%-4.7%—
IMMPImmutep LimitedFY2025A$61.41M AUD+47.8%+209.9%1217.6%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$42.41M USD-26.6%——
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$40.76M USD+72.9%——
EDITEditas Medicine, Inc.LTM Mar 2026$36.44M USD-53.4%—94.2%
HUMAHumacyte, Inc.LTM Mar 2026$17.11M USD+85.4%+27.3%848.5%
LYELLyell Immunopharma, Inc.LTM Mar 2026$2.33M USD——7522.6%
PRQRProQR Therapeutics N.V.LTM Mar 2026€1.38M EUR——10.3%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$866K USD-97.1%——
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$546K USD———
CABACabaletta Bio, Inc.LTM Mar 2026$0 USD———
Peer median (excluding CABA) —-23.8%+27.3%848.5%

Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development32.49M39.3M55.42M97.2M142.67M
Selling, General & Admin13.82M14.84M19.24M27.94M29.57M
Operating Expenses46.31M54.14M74.66M125.14M172.24M
Depreciation & Amortization733K1.18M1.43M1.71M1.65M
EBITDA(45.56M)(51.8M)(66.25M)(113.41M)(164.21M)
EBITDA Margin—————
Operating Income(46.31M)(54.14M)(74.66M)(125.14M)(172.24M)
Operating Margin—————
Interest Income24K1.16M6.99M10.03M6.03M
Interest Expense000748K2M
Other Income / Expenses24K1.16M6.99M9.28M4.39M
Income Before Tax(46.29M)(52.98M)(67.68M)(115.86M)(167.86M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(46.29M)(52.98M)(67.68M)(115.86M)(167.86M)
Net Margin—————
EPS (Basic)(1.80)(1.81)(1.65)(2.34)(1.64)
EPS (Diluted)(1.80)(1.81)(1.65)(2.34)(1.64)
Weighted Avg Shares25.74M29.34M40.95M49.52M102.26M
Weighted Avg Shares (Diluted)25.74M29.34M40.95M49.47M102.26M

Cabaletta Bio, Inc.

NASDAQ:CABA

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.